ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and markets recombinant enzymes derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics (IVD), and therapeutics in Norway, Europe, Asia, Australia, Africa, and the Americas.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr93.35|
|52 Week High||kr50.00|
|52 Week Low||kr114.40|
|1 Month Change||17.42%|
|3 Month Change||6.08%|
|1 Year Change||64.93%|
|3 Year Change||1,805.10%|
|5 Year Change||668.31%|
|Change since IPO||273.40%|
Recent News & Updates
|AZT||NO Biotechs||NO Market|
Return vs Industry: AZT exceeded the Norwegian Biotechs industry which returned 38.4% over the past year.
Return vs Market: AZT exceeded the Norwegian Market which returned 22.8% over the past year.
Stable Share Price: AZT is more volatile than 75% of Norwegian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: AZT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and markets recombinant enzymes derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics (IVD), and therapeutics in Norway, Europe, Asia, Australia, Africa, and the Americas. It offers shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing (NGS) processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; salt active nuclease for the removal of nucleic acids during manufacturing of vaccines, viruses, recombinant proteins, and other reagents; and ligases for joining DNA fragments. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020.
ArcticZymes Technologies Fundamentals Summary
|AZT fundamental statistics|
Is AZT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AZT income statement (TTM)|
|Cost of Revenue||kr1.14m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 28, 2021
|Earnings per share (EPS)||1.36|
|Net Profit Margin||62.47%|
How did AZT perform over the long term?See historical performance and comparison
Is ArcticZymes Technologies undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AZT (NOK93.35) is trading below our estimate of fair value (NOK102.47)
Significantly Below Fair Value: AZT is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: AZT is poor value based on its PE Ratio (69.6x) compared to the European Biotechs industry average (24.9x).
PE vs Market: AZT is poor value based on its PE Ratio (69.6x) compared to the Norwegian market (13.2x).
Price to Earnings Growth Ratio
PEG Ratio: AZT is poor value based on its PEG Ratio (3.9x)
Price to Book Ratio
PB vs Industry: AZT is overvalued based on its PB Ratio (21.3x) compared to the NO Biotechs industry average (3.9x).
How is ArcticZymes Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AZT's forecast earnings growth (17.7% per year) is above the savings rate (1.2%).
Earnings vs Market: AZT's earnings (17.7% per year) are forecast to grow faster than the Norwegian market (10.1% per year).
High Growth Earnings: AZT's earnings are forecast to grow, but not significantly.
Revenue vs Market: AZT's revenue (25.8% per year) is forecast to grow faster than the Norwegian market (5.7% per year).
High Growth Revenue: AZT's revenue (25.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AZT's Return on Equity is forecast to be high in 3 years time (24.7%)
How has ArcticZymes Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AZT has a high level of non-cash earnings.
Growing Profit Margin: AZT's current net profit margins (62.5%) are higher than last year (54.1%).
Past Earnings Growth Analysis
Earnings Trend: AZT has become profitable over the past 5 years, growing earnings by 69% per year.
Accelerating Growth: AZT's earnings growth over the past year (83.6%) exceeds its 5-year average (69% per year).
Earnings vs Industry: AZT earnings growth over the past year (83.6%) exceeded the Biotechs industry 19.9%.
Return on Equity
High ROE: AZT's Return on Equity (31.4%) is considered high.
How is ArcticZymes Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: AZT's short term assets (NOK201.0M) exceed its short term liabilities (NOK13.5M).
Long Term Liabilities: AZT's short term assets (NOK201.0M) exceed its long term liabilities (NOK17.6M).
Debt to Equity History and Analysis
Debt Level: AZT is debt free.
Reducing Debt: AZT has not had any debt for past 5 years.
Debt Coverage: AZT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: AZT has no debt, therefore coverage of interest payments is not a concern.
What is ArcticZymes Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AZT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AZT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AZT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AZT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AZT's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jethro Holter (49 yo)
Dr. Jethro Holter has been Chief Executive Officer of ArcticZymes Technologies ASA (formerly known as Biotec Pharmacon ASA) since April 22, 2020. He was an Interim CEO at Biotec Pharmacon ASA since October...
CEO Compensation Analysis
Compensation vs Market: Jethro's total compensation ($USD221.82K) is below average for companies of similar size in the Norwegian market ($USD616.98K).
Compensation vs Earnings: Jethro's compensation has increased by more than 20% in the past year.
Experienced Management: AZT's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: AZT's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.8%.
ArcticZymes Technologies ASA's employee growth, exchange listings and data sources
- Name: ArcticZymes Technologies ASA
- Ticker: AZT
- Exchange: OB
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr4.683b
- Shares outstanding: 50.17m
- Website: https://arcticzymes.com
Number of Employees
- ArcticZymes Technologies ASA
- Sykehusveien 23
- PO Box 6463
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 21:39|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.